BioCAD
BioCAD is a Saint Petersburg-based, privately held full-cycle biotechnology company that develops and manufactures biosimilar and originator biologics, primarily oncology, targeting blockbuster patent-expired biologics across 50+ countries in Latin America, Southeast Asia, and MENA.
- Company typePrivate
- Founded2012
- HeadquartersSaint Petersburg, Russia
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioCAD does
BioCAD (BIOCAD) is a Saint Petersburg, Russia-based, privately held full-cycle biotechnology company founded in 2001 that develops and manufactures biologic drugs across eight therapeutic areas, with primary focus on oncology biosimilars targeting blockbuster biologics whose patents have expired or are expiring. The company operates a vertically integrated platform spanning API synthesis through finished drug production, enabling end-to-end quality and supply-chain control for complex biologics. Its product portfolio includes the approved originator PD-1 inhibitor Forteca (prolgolimab), Daratumia — the world's first regulatory-approved daratumumab biosimilar referencing Johnson & Johnson's Darzalex (Russian Ministry of Health approval, August 2025) — and a pipeline candidate BCD-132 (divozilimab) for neuromyelitis optica spectrum disorder (NMOSD).
BioCAD commercializes products across more than 50 countries spanning Latin America, Southeast Asia, and the MENA region, leveraging both direct distribution and government procurement / tender channels, and benefiting from Russian domestic procurement preferences for domestically produced drugs and inclusion of its products on state VED and SSM reimbursement lists. The company reaches healthcare providers and oncology / autoimmune patients through scientific publication channels and specialist-facing portals, with clinical-trial and regulatory-approval milestones serving as primary credibility signals in lieu of traditional consumer marketing.
The business model is pharmaceutical product sales — predominantly biologics — sold through international distribution, government tenders, and reimbursement programs. Pricing is not publicly disclosed and is subject to country-specific procurement negotiation. A forward-looking strategic agreement with the Qatar Free Zones Authority (announced 2026-03-11) extends the model into manufacturing footprint expansion in the MENA region under Qatar's National Manufacturing Strategy 2024-30, targeting both import substitution and regional exports. Revenue is not disclosed in available sources.
BioCAD firmographics
Firmographics- Name
- BioCAD
- Legal name
- BIOCAD
- Website
- https://biocadglobal.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- BioCAD is a Saint Petersburg-based, privately held full-cycle biotechnology company that develops and manufactures biosimilar and originator biologics, primarily oncology, targeting blockbuster patent-expired biologics across 50+ countries in Latin America, Southeast Asia, and MENA.
- Ownership category
- akta.pro rank
BioCAD industry classification
Industry- Product category
- Biosimilar Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Oncology Biosimilars (HLAAAHAG)
- akta.pro secondary industries
- Biologics & Biosimilars Distributors (HLAIAJAH), Biologic API/Drug Substance Manufacturing Services (HLAAAKAA), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)
Keywords
Where BioCAD is headquartered
LocationHeadquarters
- HQ city
- Saint Petersburg
- HQ country
- Russia
- HQ region
- Europe
Offices2 records
Markets served
BioCAD business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Revenue model
- Biosimilar Drug Sales: Revenue generated from commercialization of biosimilar products targeting blockbuster oncology biologics whose patents have expired, marketed in over 50 countries across Latin America, Southeast Asia, and MENA regions
- Originator Drug Sales: Revenue from approved originator PD-1 inhibitor products (prolgolimab/Forteca) alongside biosimilar portfolio
Go-to-market motion1 record
Distribution channels2 records
Marketing channels2 records
BioCAD product offering
Product offeringCore offering
BioCAD is a full-cycle biotechnology company that develops, manufactures, and commercializes biosimilar and originator biologic drugs, with vertically integrated capabilities spanning API synthesis through finished drug production. Its portfolio targets blockbuster oncology biologics with expired or expiring patents (notably the world's first approved daratumumab biosimilar, Daratumia) alongside an approved originator PD-1 inhibitor (Forteca/prolgolimab) and a pipeline candidate for NMOSD (BCD-132/divozilimab). Products span oncology, autoimmune, and infectious disease therapeutic areas and are marketed in over 50 countries across Latin America, Southeast Asia, and MENA.
Product overview
BioCAD is an innovative full-cycle biotechnology company based in Saint Petersburg, Russia. The company operates a vertically integrated manufacturing model and has systematically built a two-decade biosimilar franchise targeting blockbuster oncology biologics. The product portfolio includes approved originator drugs (PD-1 inhibitor Forteca/prolgolimab), world-first biosimilar approvals (Daratumia/daratumumab), and pipeline candidates (BCD-132 for NMOSD). Products span multiple therapeutic areas including oncology, autoimmune diseases, and infectious/viral diseases, with commercial presence in over 50 countries across Latin America, Southeast Asia, and the MENA region.
Differentiator
Problem solved
Functional benefit
Brands
- BCD-132: Divozilimab/BCD-132 - pipeline drug for neuromyelitis optica spectrum disorder (NMOSD) treatment
- Daratumia
- Forteca
Products and services
- Daratumia (daratumumab biosimilar) World's first regulatory-approved daratumumab biosimilar referencing Johnson & Johnson's Darzalex, approved by the Russian Ministry of Health in August 2025 for the treatment of multiple myeloma.
- Forteca (prolgolimab)
- BCD-132 (divozilimab) Pipeline drug in development by BioCAD for neuromyelitis optica spectrum disorder (NMOSD), expected to reshape the treatment landscape for this rare autoimmune condition.
Quantifiable outcome
- World's first regulatory approval for daratumumab biosimilar (Daratumia) in August 2025
- +1 more outcomes
Companies that use BioCAD
Customer profileSegments3 records
Ideal customer profiles2 records
BioCAD technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
BioCAD partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Qatar Free Zones AuthoritycoreStrategic agreement signed with Qatar Free Zones Authority to establish pharmaceutical manufacturing facilities in Qatari free zones. This partnership is part of Qatar's National Manufacturing Strategy 2024-30 which targets QR70.5 billion in sector value-added contribution. Qatar aims to reduce its $1.13 billion annual medicine import bill and establish itself as a regional export hub.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
BioCAD competitors and assessment
Company assessmentDirect peers
- Celltrion: South Korea-based biosimilar specialist with a vertically integrated development and manufacturing model, commercializing biosimilars of blockbuster oncology and autoimmune biologics globally. Closely comparable to BioCAD in target molecule class, business model, and reliance on patent-cliff opportunities.
- Samsung Bioepis: Biosimilar-focused biotech backed by Samsung, developing and commercializing biosimilars in oncology, immunology, and ophthalmology across global markets. Highly comparable to BioCAD as a pure-play biosimilar developer with a multi-therapeutic-area commercial footprint.
- Biocon Biologics: Indian biosimilar developer with vertically integrated manufacturing and global commercial reach across oncology, autoimmune, and diabetes biologics. Directly comparable in being an emerging-market-headquartered biosimilar company competing with Western originator biologics internationally.
- Shanghai Henlius Biotech: Chinese biosimilar developer with an originator biologics pipeline, full-cycle manufacturing, and approvals across multiple geographies. Highly relevant given overlapping emerging-market positioning, biosimilar-plus-originator model, and global expansion ambitions similar to BioCAD.
- Mabxience: European biosimilar developer producing monoclonal antibody biosimilars targeting oncology and immunology reference products. Comparable to BioCAD as a multi-product biosimilar manufacturer operating in adjacent geographies with the same patent-cliff capture strategy.
Broad incumbents
- Amgen: Global large-cap biotech with both originator biologics (including PD-1 inhibitors) and a meaningful biosimilars franchise. Comparable to BioCAD as a vertically integrated developer/manufacturer of biologic oncology and autoimmune drugs with a broader portfolio.
- Pfizer (biosimilars portfolio): Global pharmaceutical major with a commercial biosimilars portfolio built through partnerships (e.g., legacy Hospira) targeting major oncology and autoimmune biologics. Comparable as a large multi-product biosimilar commercializer operating across the same regulatory markets.
- Dr. Reddy's Laboratories (biologics): Diversified Indian pharmaceutical company with a growing biologics and biosimilars franchise in oncology and autoimmune indications. Comparable to BioCAD as an emerging-market-headquartered, full-cycle biopharma targeting the same reference-product portfolio.
Emerging players
- Hetero Drugs: Indian pharmaceutical manufacturer with an expanding biosimilars portfolio across oncology and immunology, focused on emerging markets. Comparable to BioCAD in commercial focus on non-Western geographies and in pricing-sensitive tender channels.
Regional players
- Generium: Russian domestic biopharmaceutical company developing and commercializing biosimilars and originator biologics primarily within Russia and CIS. Most direct regional peer given shared Russian HQ, similar regulatory environment, and focus on domestic procurement for biosimilars targeting the same oncology/autoimmune indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
BioCAD social profiles
Digital presenceBioCAD financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioCAD leadership team
Management profileNumber of profiles
Profiles4 records
BioCAD funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioCAD M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioCAD
What does BioCAD do?
BioCAD is a full-cycle biotechnology company that develops, manufactures, and commercializes biosimilar and originator biologic drugs, with vertically integrated capabilities spanning API synthesis through finished drug production. Its portfolio targets blockbuster oncology biologics with expired or expiring patents (notably the world's first approved daratumumab biosimilar, Daratumia) alongside an approved originator PD-1 inhibitor (Forteca/prolgolimab) and a pipeline candidate for NMOSD (BCD-132/divozilimab). Products span oncology, autoimmune, and infectious disease therapeutic areas and are marketed in over 50 countries across Latin America, Southeast Asia, and MENA.
Is BioCAD a public or private company?
BioCAD is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BioCAD founded?
BioCAD was founded in 2012. It employs 501 to 1,000 people.
Where is BioCAD based?
BioCAD is headquartered in Saint Petersburg, Russia, in the Europe region.
How does BioCAD make money?
Two revenue lines are on record. Biosimilar Drug Sales are the primary driver. The others are originator Drug Sales.
Who are BioCAD's main competitors?
Direct peers on record are Celltrion, Samsung Bioepis, Biocon Biologics, Shanghai Henlius Biotech and Mabxience. Broad incumbents are Amgen, Pfizer (biosimilars portfolio) and Dr. Reddy's Laboratories (biologics). Hetero Drugs is listed as an emerging player. Generium is listed as a regional player.
Does BioCAD have an API?
No public API is recorded for BioCAD.
What industry is BioCAD in?
BioCAD's product category is Biosimilar Pharmaceuticals. Its primary akta.pro industry code is HLAAAHAG, Oncology Biosimilars, with a secondary code of HLAIAJAH, Biologics & Biosimilars Distributors. Its NAICS code is 325414 and its SIC code is 2836.